Artículo de opiniónSupervivencia en terapia biológica. ¿Sabemos a qué nos referimos? ¿ Podemos usarla?Drug Survival in Biologic Therapy. Do We Know What it Means? Can We Calculate it?
Section snippets
Conflicto de intereses
J. M. Carrascosa ha recibido honorarios en concepto de conferenciante y asesor y/o ha participado en ensayos clínicos esponsorizados por las siguientes compañías: Merck-Serono, Pfizer, MSD, Abbvie, Centocor, Janssen-Cilag, Novartis, Lilly y Amgen.
J. Notario declara haber recibido honorarios por su colaboración y participación en ensayos clínicos, ponencias y asesoría para Abbvie, Pfizer, Janssen y MSD.
Bibliografía (16)
- et al.
Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento
Actas Dermosifiliogr
(2013) Tratamiento de la psoriasis en placas moderada a grave con fármacos biológicos: análisis del sobrecoste de la intensificación temporal frente a cambio a otro biológico en caso de fracaso secundario
Actas Dermosifiliogr
(2014)- et al.
EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase iii, multicentre, double-blind trial
Lancet
(2005) - et al.
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population
J Am Acad Dermatol
(2012) - et al.
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL
J Am Acad Dermatol
(2012) - et al.
Adverse effects of biologics: A network meta-analysis and Cochrane overview
Cochrane Database Syst Rev
(2011) - et al.
Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials
Br J Dermatol
(2008) - et al.
The interpretation of long-term trials of biologic treatments for psoriasis: Trial designs and the choices of statistical analyses affect ability to compare outcomes across trials
Br J Dermatol
(2013)
Cited by (16)
Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world
2023, Journal of Geriatric OncologyTherapeutic response and survival time of immunobiologicals in patients with moderate to severe psoriasis
2022, Anais Brasileiros de DermatologiaExpert recommendations on treating psoriasis in special circumstances
2015, Actas Dermo-SifiliograficasLaunch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit
2019, Reumatologia ClinicaCitation Excerpt :We have shown, for instance, the case of UST, with no discontinuation for adverse events and ANK with nearly three times the risk of discontinuation than any other biologic agent, independently of the use. In addition, these drugs are used differently for different diseases and so a final treatment dose may be reflecting a temporary cessation due to surgery, or pregnancy, or to remission, according to the different guidelines used by the specialists.7,19–22 The Spanish Rheumatology Society and Hospital Pharmacy Society have developed a joint consensus on the optimization of biologics in patients with RA, AS, and PsA.20
Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients
2021, Pediatric Allergy and Immunology